Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P448: Remission induction therapy with tacrolimus and biological combination therapy for severe ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

A. Ito*

Tokyo Women’s Medical University, Department of Gastroenterology, Tokyo, Japan

P449: Double assessment of ileal pouch-anal anastomosis before ileostomy reversalECCO '18 Vienna
Year: 2018
Authors:

A. Gklavas1*, G. Exarchos1, L. Metaxa2, G. Karamanolis1, I. Papaconstantinou1

1Aretaieion Hospital, 2nd Surgical Department, Athens, Greece, 2St Bartholomew’s Hospital, Radiology Department, London, UK

P450: Mind the gap: Why do physicians underestimate their patient's adherence?ECCO '18 Vienna
Year: 2018
Authors:

E. Broide1,2*, A. Ein Dor1,3, A. B Shitrit4, N. Ruhimovich5, H. Shirin1,2, F.M. Konikoff3,5, T. Naftali3,5

1Assaf Harofeh Medical Center, The Kamila Gonczarowski Institute of Gastroenterology Assaf Harofeh Medical Center, Zerifin, Israel, 2Tel Aviv University Sackler School of Medicine, Internal Medicine, Tel Aviv, Israel, 3Tel Aviv University Sackler School of Medicine, Internal Medicine, Tel Aviv, Israel, 4Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel, 5Meir Medical Center, Gastroenterology, Kfar Saba, Israel

P451: Long-term surgical outcome of ileal pouch-anal anastomosis when used for well-defined Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

D. Mandel, K. Zaghiyan, P. Fleshner*

Cedars-Sinai Medical Center, Los Angeles, USA

P452: Medium to long-term outcomes in patients receiving accelerated dose infliximab induction for acute severe ulcerative colitis (ASUC) in a multi-centre cohortECCO '18 Vienna
Year: 2018
Authors:

D. Gibson1, M. McNally2*, J. Doherty1, A. Keogh2, D. Keegan1, K. Byrne1, U. Kennedy3, H. Mulcahy1, S. McKiernan3, F. MacCarthy3, L. Egan2,4, G. Cullen1,4, J. Sheridan1, S. Sengupta4,5, E. Slattery2,4, D. Kevans3,4, G. Doherty1,4

1St Vincent's University Hospital/UCD, Centre for Colorectal Disease, Dublin, Ireland, 2University Hospital Galway/NUIG, Galway, Ireland, 3St James' Hospital/TCD, Dublin, Ireland, 4Initiative IBD Research Network, Ireland, Ireland, 5Our Lady's Hospital Drogheda/RCSI, Drogheda, Ireland

P453: Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysisECCO '18 Vienna
Year: 2018
Authors:

C. Law1, A. Narula2, A. Lightner3, J.-F. Colombel4, N.P. McKenna5, N. Narula2*

1McMaster University, Internal Medicine, Hamilton, Canada, 2McMaster University, Gastroenterology, Hamilton, Canada, 3Mayo Clinic, Colon and Rectal Surgery, Rochester, USA, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, USA, 5Mayo Clinic, Surgery, Rochester, USA

P454: Early vedolizumab trough levels predict mucosal healing in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

W. Yacoub1, N. Williet2, L. Pouillon1,3*, T. Di-Bernado2, M. De Carvalho Bittencourt4, S. Nancey5, A. Lopez1, S. Paul6, C. Zallot1, X. Roblin2, L. Peyrin-Biroulet1

1Nancy University Hospital, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France, 2Saint-Etienne University Hospital, Department of Gastroenterology, Saint-Etienne, France, 3Imelda GI Clinical Research Centre, Department of Gastroenterology, Bonheiden, Belgium, 4Nancy University Hospital, Department of Immunology, Nancy, France, 5Lyon-Sud Hospital, Department of Gastroenterology, Pierre-Bénite, France, 6Saint-Etienne University Hospital, Department of Immunology, Saint-Etienne, France

P455: Spacing of infliximab infusions over 8 weeks in patients with inflammatory bowel diseases in clinical remission: Final results of a retrospective multicentre French national cohortECCO '18 Vienna
Year: 2018
Authors:

G. Dufour1*, B. Pariente2, A. Amiot3, S. Viennot4, F. Zerbib5, L. Caillo6, S. Nancey7, P. Pouderoux6, F. Poullenot5, R. Altwegg1, L. Peyrin-Biroulet8, M. Nachury2, P. Blanc1, G. Pineton de Chambrun1

1Montpellier University Hospital, Gastroenterology, Montpellier, France, 2Lille University Hospital, Gastroenterology, Lille, France, 3Henri-Mondor University Hospital, Gastroenterology, Creteil, France, 4Caen University Hospital, Gastroenterology, Caen, France, 5Bordeaux University Hospital, Gastroenterology, Bordeaux, France, 6CHU University Hospital, Department of Hepatology and Gastroenterology, Nîmes, France, 7Lyon University Hospital, Gastroenterology, Lyon, France, 8Nancy University Hospital, Gastroenterology, Nancy, France

P456: Drug survival of thiopurine–allopurinol combination therapy in a real-life population-based cohortECCO '18 Vienna
Year: 2018
Authors:

J.E. Kreijne1*, R.C. de Veer1, N.K. de Boer2, G. Bouma2, G. Dijkstra3, R.L. West4, A.A. van Bodegraven5, D.J. de Jong6, C.J. van der Woude1, A.C. de Vries1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2VU University Medical Centre, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3University Medical Center Groningen and University of Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 4Franciscus Hospital and Vlietland Hospital, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 5Zuyderland Medical Center, Clinical Gastroenterology and Hepatology, Heerlen-Sittard-Geleen, The Netherlands, 6Radboud University Nijmegen Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands

P457: Biological interventions for induction and maintenance of mucosal healing in ulcerative colitis: A Cochrane systematic reviewECCO '18 Vienna
Year: 2018
Authors:

A. Ricciuto1*, A. Al-Darmaki2, M.J. Stewart2, N.S. Ding3, H.H. Shim2, M. Storr4,5, R. Panaccione2, C. Seow2

1Hospital for Sick Children, University of Toronto, Toronto, Canada, 2University of Calgary, Medicine, Calgary, Canada, 3Imperial College Healthcare, London, UK, 4Ludwig-Maximilians-University Munich, Munich, Germany, 5Center of Endoscopy, Starnberg, Germany

P458: Long-term outcome of Crohn’s disease complicated by upper gastrointestinal stricture: A GETAID cohort studyECCO '18 Vienna
Year: 2018
Authors:

T. Lambin1*, A. Amiot2, J.M. Gornet3, P. Seksik4, D. Laharie5, E. Louis6, C. Giletta7, J. Filippi8, M. Fumery9, G. Cadiot10, G. Pineton de Chambrun11, S. Nahon12, M. Serrero13, B. Coffin14, L. Plastaras15, S. Viennot16, N. Dib17, L. Peyrin-Biroulet18, B. Pariente1

1Claude Huriez Hospital, Lille, France, 2Henri Mondor Hospital, Creteil, France, 3Saint Louis Hospital, Paris, France, 4Saint Antoine Hospital, Paris, France, 5Haut-Lévêque Hospital, Pessac, France, 6CHU Sart Tilman, Liège, Belgium, 7Rangueil Hospital, Toulouse, France, 8Hôpital de l'Archet, Nice, France, 9Hôpital Nord, Amiens, France, 10Robert Debré Hospital, Reims, France, 11Saint Eloi Hospital, Montpellier, France, 12CHI Le Raincy-Montfermeil, Montfermeil, France, 13Hôpital Nord, Marseille, France, 14Louis Mourier Hospital, Colombes, France, 15Louis Pasteur Hospital, Colmar, France, 16Hôpital Côte de Nacre, Caen, France, 17CHU Angers, Angers, France, 18Hôpital de Brabois, Vandoeuvre-les-Nancy, France

P459: Persistent mesorectal inflammatory activity is associated with complications after proctectomy in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

E.J. de Groof1, J.H. van der Meer2,3*, P.J. Tanis1, J.R. de Bruyn2,3, O. van Ruler1, G.R. D'Haens3, G.R. van den Brink2,3,4, W.A. Bemelman1, M.E. Wildenberg2,3, C.J. Buskens1

1Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands, 2Academic Medical Center (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands, 3Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 4Currently GlaxoSmithKline, Medicines Research Center, Stevenage, UK

P460: Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed childrenECCO '18 Vienna
Year: 2018
Authors:

D. Duricová1*, E. Dvorakova1, J. Kozeluhova2, P. Kohout3, K. Mitrova4, M. Durilova5, K. Zarubova4, O. Hradsky4, J. Bronsky4, N. Hradska6, E. Bronska6, N. Machkova1, V. Hruba1, M. Bortlik1, M. Lukas1, K. Malickova1, M. Lukas1

1IBD Clinical and Research Centre, Iscare, Prague, Czech Republic, 2Department of Internal Medicine, University Hospital Plzen, Plzen, Czech Republic, 3Department of Internal Medicine, Thomayer University Hospital, Prague, Czech Republic, 4Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 5Department of Paediatric Surgery, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 6General Paediatrician, Prague, Czech Republic

P461: Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

S. Travis1, R. Ungaro2, A. Blake3, F. Bhayat4*, T. Card5

1Oxford University Hospital, Oxford, UK, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Takeda International - UK Branch, London, UK, 4Takeda Development Center Americas, Inc., Cambridge, USA, 5University of Nottingham, Nottingham, UK

P462: Mucosal healing and deep remission rates with azathioprine in inflammatory bowel disease?ECCO '18 Vienna
Year: 2018
Authors:

Ü. Dağlı*, D. Özer Etik, N. Demir, S. Öcal, H. Selçuk, F. Hilmioğlu, S. Boyacıoğlu

Başkent University Medical Faculty, Department of Gastroenterology, Ankara, Turkey

P463: Long-term effects of anti-TNF therapy on bone metabolismECCO '18 Vienna
Year: 2018
Authors:

N. O'Morain1*, G. Farrell1, M. Hanly1, S. Veerappan1, D. McNamara1,2, N. Breslin1, C. O'Morain2, M. Healy3, B. Ryan1,2

1Tallaght Hospital, Gastroenterology, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3St James's Hospital, Dublin, Ireland

P464: Switching from the originator infliximab to biosimilar CT-P13 did not change the quality of life and clinical efficacy for IBD patients in stable remission in daily clinical practice (interim analysis)ECCO '18 Vienna
Year: 2018
Authors:

M.J. Pierik1, A.E. van der Meulen-de Jong2, J.P.J. Bloemsaat-Minekus3*, Y.J.B. van Megen3, G. Dijkstra4

1Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 2Leiden University Medical Center (LUMC), Leiden, The Netherlands, 3Mundipharma Pharmaceuticals B.V., Leusden, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands

P465: Do infliximab trough levels differ between adult and paediatric patients with Crohn’s disease in clinical remission?ECCO '18 Vienna
Year: 2018
Authors:

A. Cavazza1*, N. Mavroeidi1, A. Steel2, L. Greathead1, W. Kelleher1, M. Wahed1

1Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, 2The Royal Liverpool University Hospital, Liverpool, UK

P466: Acetarsol is an effective and safe option in the management of refractory ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

K. Argyriou1*, R.J.M. Ingram1, R. Blatt2, P. Wilson2, S. Samuel1, C. Hawkey1, G.W. Moran1,3

1Nottingham Digestive Diseases Centre, Queens Medical Center Campus, Nottingham University Hospitals NHS Trust, Nottingham, UK, 2Pharmacy Department, Queens Medical Center Campus, Nottingham University Hospitals NHS Trust, Nottingham, UK, 3National Institute of Health Research Biomedical Research Centre in Gastrointestinal and Liver Diseases at Nottingham University Hospitals and the University of Nottingham, Nottingham, UK

P467: A comparison of thiopurines vs. anti-TNF-α therapy in steroid-dependent ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

S. Hosomi*, M. Ohira, H. Yamagami, R. Nakata, N. Sugita, Y. Nishida, S. Itani, T. Yukawa, N. Kamata, K. Otani, Y. Nagami, F. Tanaka, K. Taira, T. Tanigawa, T. Watanabe, Y. Fujiwara

Osaka City University Graduate School of Medicine, Gastroenterology, Osaka, Japan